Anti-Parasite, Anti-Viral and Anti-Inflammatory
Here are snippets from the Testimony of Pierre Kory, MD
Homeland Security Committee Meeting: Focus on Early Treatment of COVID-19
December 8, 2020
Dr. Kory heads a non-profit organization, the Front-Line COVID-19 Critical Care Alliance, made up of some of the most highly published and well-known critical care experts in the world with almost 2,000 peer -reviewed publications in the medical literature as well as over 100 years of bedside clinical.
This group studied the use of Ivermectin, a low cost, highly effective and widely available drug to prevent and treat Covid-19 in all stages.
"Its discovery was awarded the Nobel Prize in medicine, and is already included on the WHO’s “World’s List of Essential Medicines.” We now have data from over 20 well-designed clinical studies, ten of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. This clinical data is also supported by multiple basic science, in-vitro and animal studies. Our manuscript, completed one week ago, is already out of date due to the near daily emergence of new, positive ivermectin studies. The
manuscript has been posted on the medical pre-print server OSF (Open Science Foundation) and can be downloaded here https://osf.io/wx3zn/ or on our organization’s website, www.flccc.net. A more updated meta-analysis and review authored by a group of Ph.D. researchers and scientists includes all ivermectin studies as of December 4th, 2020 and can be found on the c19study.com website here: https://ivmmeta.com/"
"These data show that ivermectin is effectively a “miracle drug” against COVID-19. The
magnitude of the effect is similar to its Nobel prize-worthy historical impacts against parasitic disease across many parts of the globe. It should be noted that that Merck, the pharmaceutical company whose scientists helped discover ivermectin, has from the first availability of the drug, donated hundreds of millions of doses for free to support the WHO parasite eradication programs. We believe a similar initiative is needed to eradicate the globe from the scourge of COVID-19. Our group held a press conference this past Friday, December 4th at the United Memorial Medical Center in Houston, issuing a “Call to Action.” We made a formal request to our national and global health care agencies and leaders to rapidly assess the growing scientific evidence on ivermectin and update treatment guidelines accordingly. We noted that the last
treatment recommendation on ivermectin is from August 27th where on the NIH website, they recommended that ivermectin only be used in clinical trials and they based that recommendation as “expert opinion” only given the lack of clinical studies at the time. There is now a wealth of studies reporting efficacy of ivermectin. In that press conference, we called for a rapid and updated review of this evidence in the hopes a treatment recommendation could be made and thus saving many thousands of lives, quickly. The press conference was broadcast via the Associated Press and Univision to nearly every country globally. The Health Ministry of the Government of Uganda is currently reviewing our manuscript with the intent of incorporating our treatment protocol into a national treatment guideline."
1) Prevention Studies: Six studies, 4 RCTs, 2 OCT’s with total patients included now over
2,400 patients – all showing near-perfect prevention of transmission of this virus in people with unprotected exposure to COVID-19 patients compared to high measured rates of transmission in those that did not receive ivermectin treatment.
2) Early treatment: Three RCT’s and multiple large case series –patients in these studies total over 3,000. All studies show either a considerable, statistically significant reduction in the number of patients who deteriorated into hospital or ICU or they reported faster recovery from all symptoms when treated with ivermectin.
3) Hospital Treatment: Four large RCT’s, 4 well designed OCT’s, total amount of patients studied approach 3,000, and almost all show large and statistically significant reductions in mortality when treated with ivermectin."
Early treatment, late treatment, pre-exposure, post-exposure to Covid trials all showed positive results. 100% of all studies showed positive results.
Case fatality rate decreases among patients over 60 in eight Peruvian states after
deploying mass ivermectin treatment. Mortality was significantly decreased in Chiapas, Mexico and Paraguay after launching the Ivermectin "deworming" protocols to avoid governmental sponsored Big Pharma suppression.
We offer these protocols and can prescribe RX as part of The Crow Nation First Indian Medical Board.
MEDICATION RECOMMENDED DOSING
lvermectin Prophylaxis for high-risk individuals: 0.2 mg/kg* dose on day 1 and day 3, then one dose/month RX
Post COVID-19 exposure prophylaxis**: 0.2 mg/kg dose on day 1 and day 3
All products can be ordered thru www.wholescripts.com
Passcode: SECOND NATURE (case and space sensitive)
Vitamin D3 1,000–3,000 IU/day Xymogen's Vitamin D3 5000
Vitamin C 1,000 mg twice daily Dr. Mercola's Super C
Quercetin 250 mg/day - Xymogen's AllerDHQ
Artemesian - 1 Tablespoon per day Quick Silver Scientific Super Artemesian
We incorporate Selenium 400 mcg, Glutathione 1-2 K injectable RX and Thymosin Alpha and Beta Peptides Injectable RX
Melatonin 6 mg before bedtime (causes drowsiness) Xymogen's CR or we can use a compounding pharmacy
Zinc 50 mg/day of elemental zinc Xymogen's Zinc Glycinate
EARLY OUTPATIENT TREATMENT PROTOCOL***
MEDICATION RECOMMENDED DOSING
lvermectin 0.2 mg/kg x 1 dose on day 1 and day 3
Vitamin D3 4,000 IU/day can go up to 10 K
Vitamin C 2,000 mg 2–3 times daily and Quercetin 250 mg twice a day
Melatonin 10 mg before bedtime can go up to 60 mg
Zinc 100 mg/day elemental zinc
Aspirin 325 mg/day (unless contraindicated)
We incorporate several German medicines based on an individual's presentation. These medicines are used in your I.V. Ozone therapy session.
References and Notes - There are 88 references in total. This is the first 11. Please contact us for the complete list.
1. Front Line COVID-19 Critical Care Working Group. MATH+ hospital treatment protcol
for COVID-19. www.flccc.net. (2020).
2. P. E. Marik, P. Kory, J. Varon, J. Iglesias, G. U. Meduri, MATH+ protocol for the
treatment of SARS-CoV-2 infection: the scientific rationale. Expert Review of Antiinfective Therapy. 10.1080/14787210.2020.1808462 (2020).
3. P. Kory, G. U. Meduri, J Iglesias, J. Varon, P. E. Marik. Clinical and scientific rationale
for the MATH+ hospital treatment protocol for COVID-19. J Int Care Med. (2020) (in
4. P. Horby, W. S. Lim, J. Emberson, M. Mafham, J. Bell, L. Linsell, N. Staplin, C.
Brightling,C., A. Ustianowski, A., E. Elmahi, B. Prudon, C. Green, T. Felton, D.
Chadwick, K. Rege, C. Fegan, L. C. Chappell, S. N. Faust, T. Jaki, A. Jeffery A.
Montgomery, K. Rowan, E. Juszczak, J. K. Baillie, R. Haynes, M. J. Landray.
Dexamethasone in hospitalized patients with Covid-19 — preliminary report. NEJM.
5. G. Rodriguez-Nava, D. P.Trelles-Garcia, M. A. Yanez-Bello, C. W. Chung , V. P.
Trelles-Garcia, H. J. Friedman. Atorvastatin associated with decreased hazard for death
in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 24,
6. G. Nadkarni, A. Lala, E. Bagiella, H. L. Chang, P. R. Moreno, E. Pujadas, V. Arvind, S.
Bose, A. W. Charney, M. D. Chen, C. Cordon-Cardo, A. S. Dunn, M. E. Farkouh, B. S.
Glicksberg, A. Kia, R. Kohli-Seth, M. A. Levin, P. Timsina, S. Zhao, Z. A. Fayad and V.
Fuster. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with
COVID-19. J Am Coll Cardio.l 76, 1815-1826 (2020).
7. M. Entrenas Castillo, L. M. Entrenas Costa, J. M. Vaquero Barrios, J. F. Alcala Diaz, J.
Lopez Miranda, R. Bouillon and J. M. Quesada Gomez. "Effect of calcifediol treatment
and best available therapy versus best available therapy on intensive care unit admission
and mortality among patients hospitalized for COVID-19: A pilot randomized clinical
study". J Steroid Biochem Mol Biol. 203, 105751 (2020).
8. X. J. Zhang, J. J. Qin, X. Cheng, L. Shen, Y. C. Zhao, Y. Yuan, F. Lei, M. M. Chen, H.
Yang, L. Bai, X. Song, M. Xia, F. Zhou, J. Zhou J, Z. G. She, L. Zhu, X. Ma, Q. Xu, P.
Ye, G. Chen, L. Liu, W. Mao, Y. Yan, B. Xiao, Z. Lu, G. Peng, M. Liu, J. Yang, L.
Yang, C. Zhang, H Lu, X. Xia, D. Wang, X. Liao, X. Wei, B. H. Zhang, X. Zhang, J.
Yang, G. N. Zhao, P. Zhang, R. P. Liu, R. Loomba, Y. X. Ji, J. Xia, Y. Wang, J. Cai, H.
Li. Clinical and translational report in-hospital use of statins is associated with a reduced
risk of mortality among individuals with in-hospital use of statins is associated with a
reduced risk of mortality among individuals with COVID-19. Cell Metab. 32, 176-87
9. L. Jehi, X. Ji, A. Milinovich, S. Erzurum, B. Rubin, S. Gordon, J. Young, M. W. Kattan,
Individualizing risk prediction for positive coronavirus disease 2019 testing: results from
11,672 patients. Chest. 158, 1364-1375 (2020).
10. Worldometer. Coronavirus Update Live. 2020;
11. British Broadcasting Corporation. Covid: What are the lockdown rules across Europe.